Biocon Ltd shares were trading at ₹412.40, down ₹2.85 or 0.69 per cent, as of 10.18 am on Tuesday, against a previous close of ₹415.25. The stock opened at ₹416.15 and has moved in a band of ₹411.20 to ₹416.70 so far in the session, with the traded volume at 10.31 lakh shares worth ₹42.55 crore.
The price action follows a regulatory filing made by the company on Monday, June 29, intimating exchanges that it had completed the acquisition of 1,15,36,956 equity shares of Biocon Biologics Ltd (BBL) from 127 selling shareholders, making BBL a wholly-owned subsidiary with effect from that date.
As consideration for the share swap, issued and allotted 87,86,362 equity shares of face value ₹5 each on a preferential basis to the 127 allottees, at an issue price of ₹376.41 per share. The allotment followed shareholder approval via postal ballot on June 7, 2026, and in-principle approval from NSE and BSE dated June 24, 2026. The newly issued shares rank pari-passu with existing equity shares.
The preferential allotment has expanded Biocon’s paid-up equity capital from ₹8,10,45,38,865, comprising 1,62,09,07,773 shares, to ₹8,14,84,70,675, comprising 1,62,96,94,135 shares. The Preferential Issue & Allotment Committee meeting that approved the move was held for 10 minutes on Monday night, between 10.00 pm and 10.10 pm.
Biocon currently has a market capitalisation of ₹66,838.13 crore, with a trailing P/E of 182.51 and an adjusted P/E of 70.19. The stock’s 52-week high of ₹440.40 was recorded on May 26, 2026, while its 52-week low of ₹331 was touched on August 11, 2025.